291 related articles for article (PubMed ID: 18676406)
1. Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
Teunissen CE; Killestein J; Kragt JJ; Polman CH; Dijkstra CD; Blom HJ
J Neurol Neurosurg Psychiatry; 2008 Dec; 79(12):1349-53. PubMed ID: 18676406
[TBL] [Abstract][Full Text] [Related]
2. Plasma homocysteine levels in multiple sclerosis.
Ramsaransing GS; Fokkema MR; Teelken A; Arutjunyan AV; Koch M; De Keyser J
J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):189-92. PubMed ID: 16421120
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
4. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
5. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.
Waldman AT; Chahin S; Lavery AM; Liu G; Banwell BL; Liu GT; Balcer LJ
Mult Scler Relat Disord; 2016 Nov; 10():73-78. PubMed ID: 27919503
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis.
Wilczak N; Ramsaransing GS; Mostert J; Chesik D; De Keyser J
Mult Scler; 2005 Feb; 11(1):13-5. PubMed ID: 15732261
[TBL] [Abstract][Full Text] [Related]
7. Elevated plasma homocysteine levels are associated with disability progression in patients with multiple sclerosis.
Oliveira SR; Flauzino T; Sabino BS; Kallaur AP; Alfieri DF; Kaimen-Maciel DR; Morimoto HK; de Almeida ERD; Lozovoy MAB; Reiche EMV; Dichi I; Simão ANC
Metab Brain Dis; 2018 Oct; 33(5):1393-1399. PubMed ID: 29797117
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
[TBL] [Abstract][Full Text] [Related]
9. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
10. Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis.
Yun JW; Cvek U; Kilgore PCSR; Tsunoda I; Omura S; Sato F; Zivadinov R; Ramanathan M; Minagar A; Alexander JS
Life Sci; 2019 Jul; 229():116-123. PubMed ID: 31082401
[TBL] [Abstract][Full Text] [Related]
11. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
[TBL] [Abstract][Full Text] [Related]
12. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
[TBL] [Abstract][Full Text] [Related]
13. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
[TBL] [Abstract][Full Text] [Related]
14. Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls.
Pawlitzki M; Uebelhör J; Sweeney-Reed CM; Stephanik H; Hoffmann J; Lux A; Reinhold D
Nutrients; 2018 Jul; 10(8):. PubMed ID: 30049983
[TBL] [Abstract][Full Text] [Related]
15. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
[TBL] [Abstract][Full Text] [Related]
16. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV
Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227
[TBL] [Abstract][Full Text] [Related]
18. Serum lactate as a novel potential biomarker in multiple sclerosis.
Amorini AM; Nociti V; Petzold A; Gasperini C; Quartuccio E; Lazzarino G; Di Pietro V; Belli A; Signoretti S; Vagnozzi R; Lazzarino G; Tavazzi B
Biochim Biophys Acta; 2014 Jul; 1842(7):1137-43. PubMed ID: 24726946
[TBL] [Abstract][Full Text] [Related]
19. Elevated HSP27 levels during attacks in patients with multiple sclerosis.
Ce P; Erkizan O; Gedizlioglu M
Acta Neurol Scand; 2011 Nov; 124(5):317-20. PubMed ID: 21208199
[TBL] [Abstract][Full Text] [Related]
20. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
